Association between polymorphisms in IL27 gene and renal cell carcinoma

References

• Atzpodien J, Kirchner H, Jonas U, et al. (2004). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–94
   PubMed Web of Science ®Google Scholar
• Basturk B, Yavascaoglu I, Vuruskan H, et al. (2005). Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30:41–5
   PubMed Web of Science ®Google Scholar
• Chiyo M, Shimozato O, Yu L, et al. (2005). Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 115:437–42
   PubMed Web of Science ®Google Scholar
• Chu H, Wang M, Yan F, et al. (2012). Polymorphisms in the IL-13 and IL-4R genes are associated with the development of renal cell carcinoma. Ann Oncol 23:2114–21
   PubMed Web of Science ®Google Scholar
• Cocco C, Di Carlo E, Zupo S, et al. (2012). Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia 26:1365–74
   PubMed Web of Science ®Google Scholar
• Decastro G.J, McKiernan JM. (2008). Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 35:581–92; vi
   PubMed Web of Science ®Google Scholar
• Devergne O, Hummel M, Koeppen H, et al. (1996). A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70:1143–53
   PubMed Web of Science ®Google Scholar
• Diakowska D, Lewandowski A, Markocka-Maczka K, Grabowski K. (2013). Concentration of serum interleukin-27 increase in patients with lymph node metastatic gastroesophageal cancer. Adv Clin Exp Med 22:683–91
   PubMed Web of Science ®Google Scholar
• Engel MA, Neurath MF. (2010). Anticancer properties of the IL-12 family – focus on colorectal cancer. Curr Med Chem 17:3303–8
   PubMed Web of Science ®Google Scholar
• Hisada M, Kamiya S, Fujita K, et al. (2004). Potent antitumor activity of interleukin-27. Cancer Res 64:1152–6
   PubMed Web of Science ®Google Scholar
• Hunter CA. (2005). New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5:521–31
   PubMed Web of Science ®Google Scholar
• Kleinrath T, Gassner C, Lackner P, et al. (2007). Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25:845–51
   PubMed Web of Science ®Google Scholar
• Li Y, Kang S, Qin JJ, et al. (2012). nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease. Gynecol Oncol 126:455–9
   PubMed Web of Science ®Google Scholar
• Lipworth L, Tarone RE, McLaughlin JK. (2006). The epidemiology of renal cell carcinoma. J Urol 176:2353–8
   PubMed Web of Science ®Google Scholar
• Liu L, Wang S, Shan B, et al. (2008). IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J Immunol 68:22–9
   PubMed Web of Science ®Google Scholar
• Matsui M, Kishida T, Nakano H, et al. (2009). Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res 69:2523–30
   Google Scholar
• Murugaiyan G, Saha B. (2013). IL-27 in tumor immunity and immunotherapy. Trends Mol Med 19:108–16
   Google Scholar
• Nakamura E, Megumi Y, Kobayashi T, et al. (2002). Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res 8:2620–5
   PubMed Web of Science ®Google Scholar
• Ngo TC, Wood CG, Karam JA. (2014). Biomarkers of renal cell carcinoma. Urol Oncol 32:243–51
   PubMed Web of Science ®Google Scholar
• Pflanz S, Timans JC, Cheung J, et al. (2002). IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16:779–90
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shimamura M, Owaki T, et al. (2006). Antiangiogenic and antitumor activities of IL-27. J Immunol 176:7317–24
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62:10–29
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63:11–30
   PubMed Web of Science ®Google Scholar
• Sole X, Guino E, Valls J, et al. (2006). SNPStats: a web tool for the analysis of association studies. Bioinformatics 22:1928–9
   PubMed Web of Science ®Google Scholar
• Wang M, Zhu XY, Wang L, Lin Y. (2013). The -607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies. PLoS One 8:e76915
   PubMedGoogle Scholar
• Xu XP, Hua LY, Chao HL, et al. (2014). Genetic association between IL-27 rs153109 polymorphism and cancer risk in Chinese population: a meta-analysis. J Recept Signal Transduct Res. [Epub ahead of print]. doi: 10.3109/10799893.2014.986743
   Web of Science ®Google Scholar
• Zhang S, Wang Y, Wang M, Ji Z. (2014a). IL-27 -964A > G polymorphism and the risk of breast cancer: a case-control study. Tumour Biol 35:12099–102
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou B, Wu Y, et al. (2014b). Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population. Immunogenetics 66:85–92
   PubMed Web of Science ®Google Scholar
• Zhu J, Qin C, Yan F, et al. (2010). IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int J Urol 17:700–7
   PubMed Web of Science ®Google Scholar